Compare Stocks: CGEN, WVE, GERN, and DSGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.56 -2.7%	$2.41	$1.29 ▼ $3.23	$248.68M	2.78	328,548 shs	163,616 shs
DSGN Design Therapeutics	$15.03 -3.2%	$14.08	$5.28 ▼ $17.25	$971.89M	1.66	553,544 shs	376,169 shs
GERN Geron	$1.51 -5.0%	$1.46	$1.04 ▼ $2.01	$1.02B	0.61	9.55 million shs	14.23 million shs
WVE WAVE Life Sciences	$4.70 -3.7%	$5.65	$4.64 ▼ $21.73	$961.59M	-1.3	3.57 million shs	6.16 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-2.66%	-7.25%	+7.56%	+21.90%	+80.28%
DSGN Design Therapeutics	-3.22%	-1.44%	+13.86%	+41.13%	+152.18%
GERN Geron	-5.03%	-1.31%	+12.27%	+29.06%	+7.86%
WVE WAVE Life Sciences	-3.69%	-8.91%	-21.67%	-17.98%	-41.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$2.56 -2.7%	$2.41	$1.29 ▼ $3.23	$248.68M	2.78	328,548 shs	163,616 shs
DSGN Design Therapeutics	$15.03 -3.2%	$14.08	$5.28 ▼ $17.25	$971.89M	1.66	553,544 shs	376,169 shs
GERN Geron	$1.51 -5.0%	$1.46	$1.04 ▼ $2.01	$1.02B	0.61	9.55 million shs	14.23 million shs
WVE WAVE Life Sciences	$4.70 -3.7%	$5.65	$4.64 ▼ $21.73	$961.59M	-1.3	3.57 million shs	6.16 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-2.66%	-7.25%	+7.56%	+21.90%	+80.28%
DSGN Design Therapeutics	-3.22%	-1.44%	+13.86%	+41.13%	+152.18%
GERN Geron	-5.03%	-1.31%	+12.27%	+29.06%	+7.86%
WVE WAVE Life Sciences	-3.69%	-8.91%	-21.67%	-17.98%	-41.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$5.00	95.31% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	9.78% Upside
GERN Geron	2.20	Hold	$4.00	164.90% Upside
WVE WAVE Life Sciences	2.81	Moderate Buy	$22.31	374.73% Upside

Current Analyst Ratings Breakdown

Latest CGEN, WVE, GERN, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00
7/31/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$15.00 ➝ $12.00
7/24/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$72.76M	3.33	$0.36 per share	7.04	$0.94 per share	2.72
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
GERN Geron	$183.88M	5.28	N/A	N/A	$0.34 per share	4.44
WVE WAVE Life Sciences	$42.73M	21.67	N/A	N/A	$2.30 per share	2.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	$35.34M	$0.38	6.74	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	25.17	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest CGEN, WVE, GERN, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	5.72	5.72
DSGN Design Therapeutics	N/A	18.86	18.86
GERN Geron	0.55	6.91	5.16
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
DSGN Design Therapeutics	56.64%
GERN Geron	73.71%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
DSGN Design Therapeutics	17.10%
GERN Geron	1.71%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	94.55 million	85.57 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

CGEN, WVE, GERN, and DSGN Headlines

Recent News About These Companies

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Analysts

3 hours ago | americanbankingnews.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

3 hours ago | marketbeat.com

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 3 at 4:05 PM | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% - Time to Sell?

September 2 at 12:19 PM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low - What's Next?

August 31, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold"

August 21, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

August 14, 2026 | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13, 2026 | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13, 2026 | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13, 2026 | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12, 2026 | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11, 2026 | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

August 10, 2026 | marketbeat.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 10, 2026 | marketbeat.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Renaissance Technologies LLC

August 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, WVE, GERN, and DSGN Company Descriptions

Compugen NASDAQ:CGEN

$2.56 -0.07 (-2.66%)

As of 09/3/2026 04:00 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Design Therapeutics NASDAQ:DSGN

$15.03 -0.50 (-3.22%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$15.04 +0.01 (+0.03%)

As of 04:59 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Geron NASDAQ:GERN

$1.51 -0.08 (-5.03%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.52 +0.01 (+0.60%)

As of 04:21 AM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

WAVE Life Sciences NASDAQ:WVE

$4.70 -0.18 (-3.69%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$4.74 +0.04 (+0.91%)

As of 05:21 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEN, WVE, GERN, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEN, WVE, GERN, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEN, WVE, GERN, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, WVE, GERN, and DSGN Company Descriptions

Compugen NASDAQ:CGEN

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEN, WVE, GERN, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEN, WVE, GERN, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEN, WVE, GERN, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN, WVE, GERN, and DSGN Company Descriptions

Compugen NASDAQ:CGEN

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools